NCT04010799View on ClinicalTrials.gov

A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

May 27, 2019

Primary Completion Date

March 8, 2021

Study Completion Date

March 8, 2021

Conditions
Cystic FibrosisNon-Cystic Fibrosis Bronchiectasis
Interventions
DRUG

CHF 6333

CHF 6333 - Part I - SAD CHF 6333 - Part II - MD

DRUG

Placebo

Placebo - Part I - SAD Placebo Part II - MAD

Trial Locations (1)

Unknown

IKF Institut für klinische Forschung Pneumologie, Frankfurt am Main

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT04010799 - A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis | Biotech Hunter | Biotech Hunter